Clinical Trials Browser

Interventional × Uterine Neoplasms × dostarlimab × Clear all

NCT05559879 2025-05-04

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms